CMC Deficiency Patterns in ANDA Review: A Systematic Review of Regulatory Expectations in Healthcare

Abstract

With a focus on the underlying causes and the changing regulatory landscape, this systematic review examines the trends of chemical, manufacturing, and controls (CMC) deficiencies in the 2020-2025 ANDA cycles. By examining twelve peer-reviewed studies, the review concludes that chemistry deficiencies account for approximately 34% of total ANDA deficiencies. Root causes of deficiency include manufacturing process controls, drug product, stability data, and bioequivalence. The importance of quality by design, digital manufacturing, and data management is emphasized as key drivers of deficiency patterns and approval efficiency. First-cycle approval rates are still low due to a lack of process understanding, insufficient scientific justification, insufficient documentation, and resource limitations as primary root causes. There is clear evidence that active quality risk management, early regulatory interactions, advanced analytics, and cross-functional collaboration can drive deficiencies down and approval efficiency up. The review also points out seven research gaps that require further research to move the frontiers of regulatory science and generic drug development.

Keywords

Abbreviated New Drug Application, Chemistry Manufacturing Controls, Generic Drugs, Regulatory Deficiencies, Quality by Design, Pharmaceutical Quality, Bioequivalence, Regulatory Science, Process Validation, Quality Risk Management.

Introduction

 

 

 

 

7.  Research Questions

The systematic review will answer five key research questions that are essential to understanding the nature of chemistry, manufacturing, and controls deficiencies in abbreviated new drug applications. These questions are aimed at understanding the deficiencies and their causes.

RQ1: What are the main categories and frequency distributions of chemistry, manufacturing, and controls deficiencies in abbreviated new drug application review cycles during the period 2020-2025? 

RQ2: What are the root causes that contribute to the chemistry, manufacturing, and controls deficiencies in generic drug development and submissions?

RQ3: In what way does the implementation of quality by design, advanced manufacturing technologies, and digital transformation activities affect the patterns of chemistry, manufacturing, and controls deficiencies and the rates of approval in the first cycle?  

RQ4: What is the regulatory expectation evolution for chemistry, manufacturing, and controls documentation requirements and quality system maturity for abbreviated new drug application submissions from 2020-2025?

RQ5: What evidence-based strategies work best in minimizing the incidence of chemistry, manufacturing, and controls deficiencies, enhancing first cycle approval rates, and shortening generic drug development times?

8. Literature Review and Related Work

The literature on chemistry, manufacturing, and controls in abbreviated new drug applications covers a variety of related topics, such as deficiency pattern analysis, bioequivalence and analytical problems, quality system implementation, the changing regulatory landscape, and factors influencing organizational adoption. Collectively, these studies provide the foundation for understanding the problem of inefficient ANDA approval.

CMC Deficiency Pattern Characterization 

The empirical study has found that the most frequent causes of CMC deficiencies in ANDAs are process description, process controls, drug product description, and stability information [1]. The most frequent types of deficiencies are the lack of an adequate basis for critical process parameters, lack of scale-up validation on an inadequate scale, inconsistencies between summaries and supporting documentation, lack of scientific rationale for acceptance criteria, and lack of stability programs. The comparisons among regions indicate that the percentage of deficiencies remains relatively constant over time and does not accurately represent the present level of regulatory uncertainty [2]. Chemistry-related deficiencies account for about one-third of the total, with an approximately equal split between bioequivalence and labeling deficiencies. 

Bioequivalence and Analytical Deficiencies 

Shortcomings in bioequivalence testing are inextricably linked to CMC through analytical methods, dissolution testing, and specifications [3]. Large-scale research has found the establishment of dissolution methods and acceptance criteria to be the most common shortcomings in bioequivalence testing, followed by shortcomings in study design and documentation. The most common shortcomings include lack of validation, lack of rationale in dissolution testing conditions, and lack of discriminatory power.   

Quality by Design and Advanced Technologies  

Quality by design (QbD) is obviously advantageous in improving process understanding, variability, and control strategy approaches [4]. However, in the generic industry, its application is not uniform because of limitations in resources, data integrity, need for statistical expertise, and lack of understanding about regulatory acceptability. Similarly, digital technologies such as process analytical technology, artificial intelligence, and data integration platforms provide enormous opportunities for real-time quality monitoring and predictive control but are limited by factors such as complexity of validation, cybersecurity, and compatibility with existing infrastructure [5]. 

Structured Data and Regulatory Framework Evolution  

Data management and CMC data model standardization have been shown to improve the efficiency of submissions and effectiveness of regulatory reviews [6]. Despite the advantages, the high costs of initial investment, data harmonization, and lack of standardization among agencies are some factors that impede implementation. At the same time, there has been a paradigm shift in the quality paradigm from traditional product-centric paradigms to lifecycle-based quality paradigms that concentrate on process understanding, risk control, supply chain management, and data integrity [7]. Modern ANDA reviews have become more holistic, not only concentrating on product quality but also on the quality of manufacturing processes.

Organizational Factors and Research Gaps  

Organizational capability and quality culture are important considerations in the emergence of deficiencies and outcomes of regulatory inspections [8]. It has been found that a high-quality system, training, and good governance practices reduce the number of inspection outcomes and enhance the quality of submissions. However, the current study is constrained by its reliance on reported deficiencies from the regulator, a lack of transparency in proprietary information, and a lack of follow-up on quality performance post-approval and pre-approval deficiencies [9]. The current study is also focused in the U.S. regulatory setting, with little comparative analysis [10].  Generally, the literature points to the existence of persistent systemic issues in ANDA CMC compliance, as well as important gaps in root cause analysis, organizational impact assessment, and evidence-based mitigation, which this review seeks to address [11].

Regulatory Framework Evolution and Quality Paradigm Shifts 

The pharmaceutical quality landscape has been shaped by globalization in manufacturing, the fast pace of new therapeutic development, innovative approaches such as continuous processing, and the recognition that traditional end-product testing is insufficient for complex products. There is a growing recognition of the need for integrated lifecycle quality management, where quality is considered end-to-end in development, manufacturing, and distribution, rather than at the end [12].  This is evident in the growing demands for process understanding, risk-based rationale for control strategies, supply chain quality assurance (including raw material suppliers and contract manufacturers), and data integrity governance to support regulatory decisions. Today’s ANDA requires not only that finished products meet specifications but also that processes produce compliant product and that quality systems prevent, detect, and correct deviations. 

Organizational Factors and Adoption Challenges 

Analysis reveals that organizational issues are more likely to prevent the implementation of quality systems than technical issues. Effective quality management helps to achieve continuous improvement if it becomes part of the routine, and quality inspections by the regulatory authority can provide important external confirmation if done in moderation. Regression analysis of cross-sectional data from drug manufacturers for the period 2004-2022, and interviews with excellence leaders, suggest that the level of maturity in quality management is a factor that largely influences the results of inspections and improvement capabilities [13]. Organizations with more mature quality management cultures, effective training, and better governance and process improvement capabilities perform better in terms of regulatory compliance and deficiencies in quality areas. 

Research Gaps and Methodological Limitations 

The current studies on the deficiencies of CMC have some limitations in terms of methods and data. The majority of the data is based on the deficiency letters reported by the regulators, rather than academic studies. This might lead to selection bias and could overlook problems that have been solved by pre-submission discussions. There are also some private limitations on accessing deficiency information [14]. It is difficult to conduct longitudinal analysis because the regulatory requirements are constantly evolving. Therefore, trends in deficiency data could represent shifting review criteria and not necessarily actual quality issues. Variability in data by dosage form, disease area, and development strategy makes it even more difficult to conduct combined analysis. Moreover, there is limited evidence available to establish the relationship between pre-approval CMC deficiencies and post-approval quality metrics such as deviations, stability issues, recalls, and shortages [15]. Also, most research is done in the context of the U.S., which makes it less generalizable to other regulators. There is also a lack of research at a root cause level, such as how deficiencies relate to company capabilities, development practices, or resource allocation. There is a lack of rigorous testing of intervention methods in a forward-looking or comparative fashion.

9.  RESULTS

RQ1: Predominant Deficiency Categories and Frequency Distributions 

Peer-reviewed literature indicates that the distribution of ANDA deficiencies is roughly even across review areas: Chemistry 34%, Bioequivalence 35%, Labeling 31%—no single, dominant delay driver. In CMC, the most frequent deficiency areas are: manufacturing process description and process controls, with typical issues: lack of clarity or unjustified critical process parameters, process robustness/scale-up validation, and inadequate characterization of critical manufacturing steps. Drug product specifications are the second most common CMC deficiency category, which includes: discrepancies between the quality overall summary and data, lack of sound rationale for acceptance criteria (notably dissolution), lack of alignment with reference-listed drug specs, and insufficient qualification of impurities/degradation products. Deficiencies in stability studies are also significant, and these are often caused by a study duration that is too short for the proposed shelf life, insufficient testing, unsuitable storage conditions, inadequate representation of batches, insufficiency of stability-indicating methods, and insufficient assessment of compatibility with container closures. Bioequivalence, although an independent area, is related to CMC through dissolution testing and analysis. Typical bioequivalence-related problems include: problems with dissolution testing/specifications (about 18%), problems with study design (16-17%), inadequate documentation of test and reference products (16%), inadequacies in bioanalytical methods (about 16%), and statistical analysis problems (10%). The trend from 2014 to 2024 indicates very little variation in the deficiency patterns, which means there are systemic issues rather than deficiencies that have been closed through guidance or communication.

RQ2: Root Causes of Persistent CMC Deficiencies

Analysis of synthesis reveals some root causes for the deficiencies in CMCs, despite the availability of guidelines and experience. The important factors are technical, and the lack of process understanding is a major concern for generic companies. They use formulation adjustments to attain bioequivalence without designing experiments or process characterization. Shortages commonly result from a lack of quality by design, with an unscientific rationale for control strategies and critical quality attributes. There is a need for better scientific rationale supported by process capability information, which is not present if there were not studies in development.  The lack of complete characterization of the reference product further hampers the development of generics. The innovator proprietary tech and the lack of information in the public domain make reverse engineering difficult, but some companies may not have the expertise to completely characterize difficult attributes such as microstructure, polymorphism, or particle size. Another significant reason is the constraints posed by organizational and resource factors. The lack of analytical infrastructure, expertise in regulatory affairs, and development budgets, particularly in the case of small or first-time ANDA filers, impedes data generation and submission, which is further challenged by the generic market environment.   Systemic problems also exist: a lack of integration between development and regulatory documents, silos between teams, and unconnected submissions that lack a scientific story. Complex supply chains and contract manufacturers add further knowledge transfer gaps in technology transfer and scale-up. Finally, the increasing regulatory requirements and differences in interpretation of guidance make it difficult to know what constitutes acceptable process understanding and depth of documentation, especially for complex products. This may result in a lack of adequate justification or over-documentation, posing a risk of regulatory deficiencies.

RQ3: Impact of Quality by Design and Technology on CMC Deficiencies 

Quality by Design (QbD) can help overcome the limitations of CMC by improving process understanding, risk management, and scientific decision-making. There is evidence that QbD can help in understanding key quality attributes, formulation-process-quality relationships by Design of Experiments, definition of design spaces, and development of efficient control strategies. The advantages include improved process capability, reduced variability, reduced deviations, and consistent commercial performance. The regulatory environment gets clear specifications, control strategies, and change management rationale, with potential flexibility in approved design spaces.  However, the implementation of QbD in the generics sector is not consistent. The level of complexity in the experiments, analysis, modeling, and validation of QbD is not within the budget and time limitations. In-house expertise in experimental design, process modeling, and quality risk management is not present, and data integrity and record-keeping need validated electronic records. Digital technology, including process analytical technology (PAT), artificial intelligence/machine learning (AI/ML), and advanced data management, also has advantages in deficiency reduction. PAT allows for real-time process observation and early anomaly detection, while AI/ML allows for predictive quality and root cause analysis. It has not been widely adopted due to difficulties in validating adaptive algorithms and cybersecurity risks in networked systems. Data management systems make the process of data entry and review easier by using standardized terms, automated validation, and better data access. The cost of implementation, changes in the organization, and lack of harmonized data standards for regulatory data are some of the factors that impede the implementation of data management systems.

RQ4: Regulatory Expectation Evolution During 2020-2025 

The needs for CMC documents and the establishment of the quality system have undergone a paradigm shift from 2020 to 2025. This paradigm shift is from end product testing to a life cycle approach for quality assurance. The current ANDA submission process includes process characterization, sound scientific control strategies, and process understanding, in addition to finished product specifications.  Although quality by design (QbD) is not formally required, there is an expected increased focus on risk assessment, process understanding, and rationales for control strategies. In essence, a development approach that embodies the principles of QbD is being sought. There is a hope to observe a scientific link between specifications and controls, critical quality attributes, process capability data that provides evidence of consistent performance, and justifications for proposed controls to ensure quality. There has been a growing concern about data integrity problems, which have been identified as a consequence of past failures in compliance. At present, there is a growing need for validated electronic systems with full audit trails, secure data storage, controlled access, and backups at all stages, including formulation studies, method validation, process optimization, and stability studies. There is also a greater focus on the topics of comparability of clinical and commercial data, proper technology transfer, and full end-to-end management of the supply chain, including raw materials and contract manufacturers. The publicly available complete response letters have made it easier to see the patterns of deficiencies and the reasoning behind the regulatory decisions, which has had an impact on industry practices. Despite the continuous alignment of international regulations through ICH guidelines, there are still big differences among jurisdictions. Generic companies applying for approvals in different regions face different requirements for bioequivalence study, dissolution, process validation, and stability, making global development more complicated.

RQ5: Evidence-Based Deficiency Reduction Strategies 

Analyzing the reviewed literature reveals several approaches to reduce CMC issues and increase the rate of first-cycle approvals. Pre-meetings with the regulators, such as pre-ANDA meetings, protocol submissions, or managed correspondence, are useful to reach a common understanding on development strategies and identify potential risks before making large investments. When done with Quality by Design and adequate resources, development can create strong process understanding and a robust control strategy. This is achieved through: identifying and focusing on critical quality attributes based on risk; employing design of experiments to understand the relationship between formulation, process, and quality; employing statistical models to define safe operating ranges; and developing controls that focus on sources of variability rather than final product testing. Improved analytical work using sophisticated techniques enhances our justification of specifications and demonstration of equivalence. Methods such as impurity profiling, particle size and polymorphism analysis, and excipient compatibility studies can alleviate typical concerns of reviewers.   Internal pre-submission quality checks also reduce deficiencies. Quality checks can be done by using checklists, having review teams, performing mock regulatory reviews, and conducting gap analyses based on review questions to enhance the completeness and clarity of the documentation. Engagement with formulation, analytical, manufacturing, and regulatory groups can improve knowledge transfer and ensure that the scientific rationale is evident. Early and ongoing regulatory engagement can prevent gaps between development activities and how they are represented to the regulators. For complex generics, product-specific guidance's provide focused guidance on bioequivalence approaches, critical quality attributes, analytical approaches, and what documents are required, thus reducing development uncertainty.

10.  RESULTS

Integration of Technical and Organizational Factors 

Evidence indicates that the successful development of CMCs and the approval of ANDAs require a combination of technical expertise with knowledge of the organization and regulations. A deep understanding of process, analytical characterization, and process control are critical for developing quality products and approvable submissions. However, organizational considerations such as resource management, depth of knowledge, coordination, and regulatory acumen can make technical efforts into regulatory successes.  This interaction helps to explain the patterns of deficiency that continue to be observed despite advances in analytics and guidance. Some organizations have strong technical capabilities but not necessarily the regulatory presentation to demonstrate equivalence and support specs. Others have strong regulatory capabilities but not necessarily the analytical or manufacturing capabilities.

Quality by Design Promise and Implementation Reality 

Quality by design (QbD) supports the regulatory requirements of science-based development, improved process understanding, reduced variability, and rationalized control strategies. There is an increase in the quality of submissions, deficiencies, and commercial manufacturing performance for companies that implement QbD. But the implementation of QbD is still low, especially among small generic firms. This is because the complete implementation of QbD requires high investment in experiments, modeling, and experts, which may not be feasible for generic development. Also, the lack of clarity on the acceptance of design space by the regulatory authority makes it less attractive to invest. Therefore, the implementation of QbD is categorized into two groups: large-scale manufacturers and complex product developers implement complete QbD, while small firms implement selected aspects of QbD, including risk analysis and experimental activities. More implementation of QbD can be expected with increased support from the regulatory authority for QbD in generic products, clear guidelines on design space, and simplified QbD for simpler products.

Digital Transformation Opportunities and Obstacles 

Technologies such as PAT, AI, and data management can be leveraged to enhance the quality assurance and regulatory part of the pharmaceutical industry. Real-time monitoring assists in the early identification of any anomalies; AI assists in the development of predictive models of quality and pattern recognition; data management systems can be utilized for preparing submissions and assisting in the regulatory review process by automatically performing consistency checks. The adoption rate is low in the generic category. The factors that could impede the adoption of digital transformation are the lack of clarity in the validation process of adaptive algorithms, the growing need for cybersecurity in networked systems, compatibility with existing systems, and high capital expenditures. ROI could be more important than benefits for companies with smaller product lines or lower margins. Therefore, the digital transformation process is likely to be a gradual one, with selective adoption in high-value segments rather than industry-wide. Large companies are likely to have a better chance of reaping benefits from digital transformation, and this could lead to a performance gap in the industry.

Regulatory Framework Evolution and Industry Adaptation   

The regulatory requirement drift is moving towards quality management based on the lifecycle approach, risk decisions, and process understanding. End-product testing is no longer adequate to ensure quality in complex manufacturing and global supply chains. This paradigm shift is beneficial to companies with high-quality systems and process understanding, but it is a challenge for small companies with limited resources. The regulatory agencies are faced with the dilemma of ensuring high quality standards while ensuring that the generic drug market is accessible and competitive.

CONCLUSION

This systematic review of 12 peer-reviewed articles (2020-2025) will examine the deficiencies in chemistry, manufacturing, and controls (CMC) during ANDA submissions. Deficiencies in CMC account for approximately 34% of all ANDA deficiencies, with the largest deficiencies in manufacturing process controls, drug product, and stability. Deficiencies in bioequivalence will be examined in a separate section but are also important in the context of CMC dissolution testing. The deficiencies in understanding, analytical characterization, knowledge of the reference product, resource constraints, expertise, lack of cross-functional integration, and changing regulations are not remedied by training and education. Deficiencies in capabilities are not remedied by guidance documents.     Quality by design, technology, and data can assist in reducing deficiencies by enhancing process understanding, control, and submission efficiency. However, high resource intensity, complexity of validation, and uncertain return on investment make it less desirable, especially for small companies. The current regulatory requirements include lifecycle quality management, risk-based approaches, and data integrity. Overcoming the deficiencies in CMC is critical for fast-track generic approval and quality. This review provides an evidence-based platform for collaboration between the industry, the regulatory agency, and scientists for effective quality improvement.

REFERENCES

1. Kumar, J., Ramkishan, A., & Venkatesh, M. P. (2023). Bridging the gap: Aligning GMP requirements for generic manufacturing across the US, EU and Japan. International Journal of Pharmaceutical Investigation, 13(3), 432. https://doi.org/10.5530/ijpi.13.3.054
2. Ullagaddi, P. (2024). FDA warning letter trends: A 15-year analysis. Journal of Pharmaceutical Research International, 36(10), 14. https://doi.org/10.9734/jpri/2024/v36i107585
3. Dupont, M. (2025). Stability and bioequivalence challenges in generic drug formulation: A regulatory perspective. GSC Biological and Pharmaceutical Sciences, 31(2), 166. https://doi.org/10.30574/gscbps.2025.31.2.0189
4. Ameen, S. A., & Pappula, N. (2023). Analytical QbD approach to redefine the quality of pharmaceuticals: A review. Journal of Pharmaceutical Research, 22(4), 178. https://doi.org/10.18579/jopcr/v22.4.81
5. Krishnan, P. S., Krishnan, N. J. S., Dey, A., Sivakumar, S., Ravichandran, S., & Bharathi, M. P. G. (2025). Tech-driven trust: The role of AI and emerging technologies in pharmaceutical quality assurance. International Journal of Applied Pharmaceutics, 17(5), 122. https://doi.org/10.22159/ijap.2025v17i5.54474
6. Ahluwalia, K., Abernathy, M. J., Algorri, M., Cauchon, N. S., Perico-Norred, N. M., & Youssef, R. Y. A. (2025). The future of regulatory filings: Digitalization. AAPS Open, 11(1). https://doi.org/10.1186/s41120-025-00113-7
7. Weitzel, J., Pappa, H., Banik, G. M., Barker, A. R., Bladen, E., Chirmule, N., DeFeo, J. A., Devine, J., Emrick, S. P., Kass-Hout, T., Levy, M. S., Mahlangu, G., Rellahan, B. L., Venema, J., & Workman, W. E. (2021). Understanding quality paradigm shifts in the evolving pharmaceutical landscape: Perspectives from the USP Quality Advisory Group. The AAPS Journal, 23(6). https://doi.org/10.1208/s12248-021-00634-5
8. Guha, B., Moore, S., & Huyghe, J. M. (2023). Application and validation of machine vision inspection for efficient in-process monitoring of complex biomechanical device manufacturing. Journal of Engineering and Applied Science, 70(1). https://doi.org/10.1186/s44147-023-00242-4
9. Aglave, G., Yerram, S., Patnam, J. D., Ajmal, C. S., Nizam, V. P. M., Joga, R., Raghuvanshi, R. S., & Srivastava, S. (2024). Proactive approaches to cGMP compliance: Insights and key takeaways from USFDA warning letters to pharmaceutical industries between 2019 and 2024. Journal of Pharmaceutical Innovation, 19(4). https://doi.org/10.1007/s12247-024-09857-3
10. Lin, J. C., Jain, B., Iyer, J. M., Rola, I., Srinivasan, A., Kang, C., Patel, H., & Parikh, R. B. (2025). Benefit-risk reporting for FDA-cleared artificial intelligence–enabled medical devices. JAMA Health Forum, 6(9). https://doi.org/10.1001/jamahealthforum.2025.3351
11. Alam, A. M. ul. (2024). Analyzing FDA Form 483 data of 2023: Identifying trends and areas of concern in regulatory compliance. Journal of Pharmaceutical and Biological Sciences, 12(1), 3. https://doi.org/10.18231/j.jpbs.2024.002
12. Duarte, J., Duarte, M. de S., Piedade, A. P., & Mascarenhas-Melo, F. (2025). Rethinking pharmaceutical industry with quality by design: Application in research, development, manufacturing, and quality assurance. The AAPS Journal, 27(4), 96. https://doi.org/10.1208/s12248-025-01079-w
13. Bernasconi, M., Friedli, T., & von Dzengelevski, O. (2025). The impact of current good manufacturing practices inspections on continuous improvement mindset in the pharmaceutical industry. Journal of Pharmaceutical Innovation, 20(6). https://doi.org/10.1007/s12247-025-10200-7
14. Wiedmann, L., Blumenau, J., Carroll, O., & Cairns, J. (2024). Using automated text classification to explore uncertainty in NICE appraisals for drugs for rare diseases. International Journal of Technology Assessment in Health Care, 40(1). https://doi.org/10.1017/s0266462323002805
15. Sreed, A., R, V. L., Janodia, M. D., & Ligade, V. S. (2024). Enhancing profitability of complex generics: A comparative study of market dynamics in United States and India. Research Square. https://doi.org/10.21203/rs.3.rs-5331743/v1